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Abstract
Objectives Seroprevalence studies to assess the spread of SARS-CoV-2 infection in the general population and subgroups
are key for evaluating mitigation and vaccination policies and for understanding the spread of the disease both on the
national level and for comparison with the international community.
Methods Corona Immunitas is a research program of coordinated, population-based, seroprevalence studies implemented
by Swiss School of Public Health (SSPH?). Over 28,340 participants, randomly selected and age-stratified, with some
regional specificities will be included. Additional studies in vulnerable and highly exposed subpopulations are also
planned. The studies will assess population immunological status during the pandemic.
Results Phase one (first wave of pandemic) estimates from Geneva showed a steady increase in seroprevalence up to 10.8%
(95% CI 8.2–13.9, n = 775) by May 9, 2020. Since June, Zurich, Lausanne, Basel City/Land, Ticino, and Fribourg
recruited a total of 5973 participants for phase two thus far.
Conclusions Corona Immunitas will generate reliable, comparable, and high-quality serological and epidemiological data
with extensive coverage of Switzerland and of several subpopulations, informing health policies and decision making in
both economic and societal sectors.
ISRCTN Registry: https://www.isrctn.com/ISRCTN18181860.
Keywords Prevalence  Serosurvey  Longitudinal  SARS-CoV-2  Socioeconomic differences  Hygiene practices
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This cohort study has been deemed a ‘‘Category A’’ research
project according to HRO Art. 7, as the planned data
collection entails only minimal risks and burden to patients.
Other seroprevalence studies of SARS-COV-2-antibodies
under the umbrella of Corona Immunitas by SSPH?,
following mainly the same protocol, have already been
approved by the local ethics commissions and already started
in the Canons of Geneva (SEROCoV-POP study; Project
Leader Dr. Silvia Stringhini, BASEC No 2020-00881),
Ticino (Corona Immunitas Ticino; Project Leader Prof. Dr.
Emiliano Albanese, BASEC No 2020-01514) and Vaud
(UnderCOVer study; Project Leader Prof. Valérie
D’Acremont, BASEC No 2020-00887). In the Cantons Basel
Landschaft and Basel Stadt, the project has been submitted to
the local ethics commission (CoV-Co-Basel, Project Leader
Prof. Dr. Nicole Probst-Hensch, BASEC No 2020-00927).
Electronic supplementary material The online version of this
article (https://doi.org/10.1007/s00038-020-01494-0) con-
tains supplementary material, which is available to autho-
rized users.
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Introduction
ByAugust 21, 2020, over 22,000,000 persons were diagnosed
with a severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2) (Gorbalenya et al. 2020) infection globally
and the number of deaths exceeded 790,000 (Worldometer
2020). Switzerland alone had over 39,000 confirmed cases
with over 1700 deaths (Federal Office of Public Health
(FOPH) 2020a). The 2019 novel coronavirus (COVID-19)
pandemic has caused worldwide lockdowns and restrictions
on individuals’ freedom of movement to limit the spread of
this virus.Themeasures takenby theSwissgovernment aimed
to balance the protection of the population against SARS-
CoV-2 and the functioning of the economy and society at
large. As the number of cases rose in March 2020, a con-
tainment strategy of contact tracing and isolation was not
enough (Hellewell et al. 2020) and the countrywasquickly put
into a semi-lockdown. Non-essential businesses were closed,
citizens were asked to stay at home, and distance learning for
all schools was implemented (FOPH 2020b). Later, with the
flattening of the pandemic curve and increasing political
pressure, the semi-lockdown was progressively lifted. These
decisions had, and still have, to be taken, while many epi-
demiologic features of the SARS-CoV-2 pandemic are
unknown, such as transmission characteristics of the virus,
prevalence of infection, extent of immunity after infection and
its relationship to disease symptoms and severity, and how
different groups of the population are affected. To overcome
this, it is crucial to monitor the pandemic and increase our
knowledge about the virus with solid data to inform future
policy decisions and help prepare potential future outbreak
responses in a balanced manner (Arora et al. 2020).
Seroprevalence surveys are designed to assess the pro-
portion of populations infected by the virus, where diag-
nostic testing fails to ascertain the full scale of the spread
due to unreported and asymptomatic cases. However,
weaknesses and between-study differences in methodology
limit their reliability and comparability. A rapid, systematic
review of early seroprevalence surveys by Bobrovitz et al.
(preprint) on SARS-CoV-2 came out identifying 73 com-
pleted and ongoing seroprevalence studies across the
world. These studies reported seroprevalence estimates
ranging between 0.4 and 59.3%. The review found that, of
the 23 studies reporting prevalence estimates, many had a
moderate or high risk of bias (Bobrovitz et al. 2020; Joanna
Briggs Institute 2016). Reportedly, the largest issues with
these early studies included inadequate sampling methods
and antibody test performance, lack of or inconsistent use
of questionnaire assessments, and varying designs and
analyses, hindering comparison of results.
To overcome these limitations and generate information
about the SARS-CoV-2 pandemic that is accurate and
generalizable to the whole population, population-based
seroprevalence studies with reliable methodologies are
needed (Pollán et al. 2020). It is essential to include strong
coordination across study sites and to ensure cross-regional
comparability. Standardized methodologies, including the
same antibody tests, questionnaires, and study procedures,
are vital to obtain reliable estimates within a country
(World Health Organization (WHO) 2020). Further, an
additional understanding of the duration of immunity,
demographic differences, and the economic and psycho-
logical impact of the pandemic and subsequent control
measures adds more depth and understanding of the overall
situation. This further helps inform policy-making and
provides better preparedness, both logistically and with
respect to the economic consequences, for any future
outbreaks.
We describe here the protocol of Corona Immunitas, a
centrally coordinated research program consisting of
repeated cross-sectional and longitudinal seroprevalence
and seroepidemiological studies conducted across several
regions and populations in Switzerland, whose aim is to
generate reliable data to inform policy-making.
Study objectives
The main goal of the Corona Immunitas research program
is to determine the extent and nature of infection with
SARS-CoV-2 in Switzerland in a highly consistent and
comprehensive way, first, in the general population and,
second, in vulnerable and highly exposed subpopulations.
Specific aims are to: (1) estimate the number of individuals
infected with SARS-CoV-2 in the population with or
without symptoms at several points in time; (2) compare
the seroprevalence between the general population and
specific subpopulations; (3) investigate the characteristics,
duration, and extent of immunity after infection; (4) assess
the association between participant characteristics and
behaviors with their risk of infection; and (5) quantify the
association between the pandemic and participants’ mental
and physical health. Most importantly, this evidence-based
program aims to provide policy-makers and other decision
makers with important evidence for deciding which public
health and setting-specific measures to implement or lift in
the general population and specific subpopulations at dif-
ferent points in time.
Methods
The protocol has been developed according to the Con-
sortium for the Standardization of Influenza Seroepidemi-
ology (CONSISE) Statement on the Reporting of
E. A. West
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Seroepidemiologic Studies for Influenza (ROSES-I)
(Joanna Briggs Institute 2016).
Study design and phases of the Corona
Immunitas program
The Corona Immunitas program includes more than 20
cross-sectional and longitudinal studies in the general
population and in specific subpopulations (Tables 1 and 2)
with serological testing at baseline and a digital only or
combined digital and serological follow-up. The ques-
tionnaires and the antibody test are standardized across the
sites to guarantee comparability across the country. The
Corona Immunitas research group shares protocols for all
the studies in an open science way in order to exchange
knowledge and expertise, to create synergisms but also to
reduce redundancies across cantons and regions. We define
our general, population-based studies as seroprevalence
studies and our subpopulation studies as seroepidemio-
logical studies per the lexicon defined by Horby et al.
(2017).
The studies are conducted in a series of repeated phases,
the timing of which is subject to change according to the
highly dynamic pandemic and additional needs that may
emerge (Fig. 1). The first phase began in April 2020 and
included early estimates of seroprevalence during the first
wave from Geneva (Stringhini et al. 2020). The second
phase includes estimates of seroprevalence across
Switzerland during summer, after the first peak of the
pandemic. This phase, conducted as recommended by the
WHO protocol (WHO 2013) after the (first) pandemic
wave, includes highly (Cantons of Geneva, Vaud and
Ticino), moderately (Cantons of Fribourg, Neuchatel and
Basel City/Land) and little affected regions of Switzerland
(Cantons of Zurich and St. Gallen) (FOPH 2020a). The
third phase will be in the fall and includes estimates of
seroprevalence across Switzerland about 4–5 months after
the lifting of lockdown measures. This phase will help
evaluate the quality of the monitoring systems in place and
determine the needs for a vaccination program. A fourth
phase will cover March 2021 and will evaluate the mea-
sures after the winter, as well as the completeness and
duration of immunity.
General population seroprevalence studies
Geneva was the first canton to enroll randomly selected
participants of a population-based study (Bus Santé)
ongoing since 1993 (Stringhini 2020). For the other Can-
tons, the Federal Statistical Office (FSO) randomly selec-
ted, per region, potential participants from the residential
registry. The number of randomly chosen participants takes
into consideration the net sample size (i.e., target sampleTa
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size) as well as the expected participation rate and reserve
samples (residents selected in the case that more partici-
pants are needed to fulfill the sample size requirements).
The FSO provides all participating Cantons with a list of
participants, including their full name, postal address and
preferred language. The sampling is age-stratified into
three age groups: 5–19 years, 20–64 years, and 65 years
and older, though some Cantons have also chosen to recruit
younger participants. Cantons can choose slightly modified
sampling procedures, such as recruiting participants’ fam-
ily or household members (Table 1).
The inclusion criteria for the random sampling are res-
idency in one of the participating Cantons. ‘‘Vulnerable to
COVID-19 persons’’ (detailed below) are included. For
inclusion in the data collection, individuals with a sus-
pected or confirmed acute SARS-CoV-2 infection are
postponed for a visit to 48 h after disappearance of
symptoms or 21 days after a positive SARS-CoV-2 reverse
transcription polymerase chain reaction test (RT-PCR)
result. Excluded from the residential registry of the FSO
are diplomats, persons with a foreign address in the reg-
istry, persons in asylum procedure, persons with a short-
term residence permit, and elderly people in nursing
homes.
If selected, ‘‘vulnerable to COVID-19 persons,’’ i.e.,
persons at risk of a severe course of SARS-CoV-2 infec-
tion, can participate. They are defined in accordance with
the recommendations by the Swiss Federal Office of Public
Health (FOPH) (FOPH 2020c). The handling of those
participants vulnerable to COVID-19 varies depending on
the site. Persons are considered at risk of a severe course of
SARS-CoV-2 infection if they are 65 years of age or older,
pregnant or if they have the following conditions: diabetes;
cardiovascular disease; chronic diseases of the respiratory
tract; immune weaknesses due to disease or therapy; can-
cer(s); and obesity defined by a body mass index
(BMI)[ 30 kg/m2 for adults and above the 97th percentile
of Swiss BMI growth curves for children and adolescents
(https://www.paediatrieschweiz.ch). While the FOPH con-
siders persons with high blood pressure to be at risk, the
Swiss Hypertension Society recommends applying the
same precautionary measures for hypertensive patients as
for the rest of the population (Swiss Society of Hyperten-
sion 2020).
Subpopulation seroepidemiological studies
Corona Immunitas also includes specific subpopulations
deemed especially exposed or vulnerable and about which
more knowledge is necessary to inform policy- and deci-
sion making. Each center decided which subpopulation
should be targeted based on the needs of stakeholders (e.g.,
Cantonal health authorities) or scientific interest. These
studies follow the same study protocol as the general
Fig. 1 Phases of the pandemic as defined in the Corona Immunitas program (Switzerland 2020–2021)
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population but may include additional questions (e.g.,
characteristics or specific participant-reported outcomes).
Figure 2 and Table 2 show a comprehensive overview of
these subpopulation studies, notably nursing home resi-
dents and staff, healthcare workers, school students,
teachers, and parents.
Study recruitment and informed consent
Participants of the general and subpopulation studies are
invited to participate by postal mail or email. The invitation
requests that interested participants make an appointment
for a baseline assessment and contains information about
the study, a declaration of consent, and an electronic link
that will allow them to complete a baseline questionnaire
online. Feedback of the serology test to participants is
handled individually by the sites and subject to variations.
Baseline assessment
An example of the full study flow is outlined in Fig. 3.
Informed written or electronic consent is obtained before
any procedure of the study visit. Participants can fill the
baseline questionnaire online or use a paper form. The
questionnaire takes approximately 20 min to complete and
includes demographic questions, symptoms, other tests
taken for SARS-CoV-2, preventative measure behaviors,
and quality of life measures. Details of the questions asked
of the participants are given in Table 3. The full ques-
tionnaires used nationwide are published in the online
supplementary material.
Fig. 2 Overview of seroprevalence studies in Switzerland (Corona
Immunitas 2020–2021). ZH Zurich, BE Bern, LU Luzern, UR Uri, SZ
Schwytz, OW Obwald, NW Nidwald, GL Glarus, ZG Zug, FR
Fribourg, SO Solothurn, BS Basel-City, BL Basel-Land, SH
Schaffhausen, AR Appenzell Ausserrhoden, AI Appenzell Innerrho-
den, SG St. Gallen, GR Graubünden, AG Aargau, TG Thurgau, TI
Ticino, VD Vaud, VS Valais, NE Neuchâtel, GE Geneva, JU Jura,
PrEP Pre-exposure prophylaxis for HIV prevention. See Tables 1 and
2 for a detailed description of the studies. (Corona Immunitas,
Switzerland, 2020–2021). *Children study with white bottoms instead
of blue bottoms means there is no population-based children’s study
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Venous blood sampling is performed at a blood collec-
tion site or at home. All staff have access to the necessary
infrastructure for blood withdrawal and safe storage of
biological samples. The entire process follows Standard-
ized Operating Procedures (SOPs). Blood drawing is per-
formed by trained healthcare staff (i.e., nurse, assistant
nurse, or junior doctor). The quantity of blood varies
according to the study site, and depending on whether
additional analyses are performed. Standard hygiene rules
are followed such as usual handwashing, disinfection pro-
cedures, and wearing of masks and gloves. All participants
are required to wear a mask, provided by the study team,
during all interactions.
Samples are transported to a local laboratory or the
Vaud Central University Hospital (CHUV) directly or
centrifuged before transport to the laboratory if possible,
aliquoted and stored in a biobank on each site at - 20 C
or - 80 C before the serological test. Samples are deliv-
ered within 16 h of being taken. Team members are trained
in safe management practices and procedures for contam-
ination accidents. Serum is prepared with serum gel and
plasma with ethylenediaminetetraacetic acid (EDTA)
before the serology test. Depending on the site, serum or
plasma from the drawn venous blood is analyzed for the
presence of SARS-CoV-2 IgG and IgA antibodies. Some
study sites will store additional serum, saliva or plasma
samples in a biobank for further use in this or in other
studies; genetic and epigenetic analyses are planned in
several centers. Participants are informed about the planned
analyses and provide broad consent for future research use
of biospecimens.
The study data are collected and managed using RED-
Cap electronic data capturing tools (Harris et al. 2019)
hosted at the responsible universities. Websites of study
centers are fully detailed in the supplementary material
Table S1.
Selection of antibody tests
The selection of a common test followed a stepwise pro-
cedure. We developed a set of criteria (see supplementary
material Table S2) that refer to the nature of the test, results
from validation studies and the logistics and cost of the
test. Members of the Corona Immunitas consortium
Fig. 3 Example study flow of seroprevalence studies (Corona Immunitas, Switzerland, 2020–2021)
E. A. West
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independently rated the tests that were submitted for use in
our program, and compiled a ranking (Corona Immunitas
2020). While specificity was high for most tests, which is
crucial when seroprevalence is low, there was evidence of
limited sensitivity. Most validation studies are likely to be
substantially biased (e.g., spectrum bias and differential
verification bias) because of their designs according to
recent systematic reviews (Corona Immunitas 2020; Deeks
et al. 2020). Biased estimates of accuracy make the
adjustment of seroprevalence estimates for (imperfect)
sensitivity and specificity uncertain. Therefore, the mem-
bers decided to use the SenASTrIS (Sensitive Anti-SARS-
CoV-2 Spike Trimer Immunoglobulin Serological) assay
developed by the CHUV, the Swiss Federal Institute of
Technology in Lausanne (EPFL) and the Swiss Vaccine
Center as the common test (Fenwick et al. 2020). Reasons
for this choice were the trimeric (entire S) target, the strong
signal detected in persons with and without symptoms at
the time of infection, the availability of IgG and IgA, the
specificity of 99.7% and no cross-reactive antibodies in
sera from people infected with pre-pandemic coron-
aviruses, a high sensitivity of 96.6% post 15 days of
infection, superior performance over commercial tests in
population-based samples that missed up to 45% of
seropositive persons, the possibility for quantification, the
availability of a neutralizing antibody test, the evidence of
superior performance in population-based samples in
comparison with six commercial tests, the availability of
test material, and the possibility of use of this Luminex-
based test in other laboratories in Switzerland (Fenwick
et al. 2020).
Longitudinal follow-up
A digital follow-up will be conducted for a duration of
6–12 months, depending on the progression of the pan-
demic, allowing for tracking the health status of individuals
and for identifying new infections through reports of flu-
like symptoms. The digital follow-up consists of weekly,
brief status updates with respect to self-reported symptoms
Table 3 Example of schedule of assessments (Corona Immunitas, Switzerland, 2020–2021)
Contacts Invitation/
recruitment
Study visit
(BL)
Digital follow-up
Timing Prior to Day 0 Day 0 Week 1 to week 52 (weekly)
Study invitation X
Invitation for Baseline data collection (and visit—depending on center) X
Confirmation letter or email, written information X
Baseline questionnaire (online):
Personal demographics & health data
COVID-19 specific data; including symptoms, hospitalization, relevant
medications, other SARS-CoV-2 tests
Socio-demographic data
Economic impact due to lockdown measures
Persons in immediate vicinity and their relevant symptoms
Preventive measures, exposure and level of concern over pandemic
X X
Oral and/or written information X
Check inclusion-/ exclusion criteria X
Written consent X
Blood sampling X
Information on test interpretation X
Information on digital follow-up X
Information on further procedure according to subpopulation X
Weekly digital follow-up questionnaire (online):
Symptoms, healthcare professional contacts, hospitalizations, test results,
preventive measures
X
Monthly digital follow-up questionnaire (online):
Access to health care, behavior, daily activities, mental health, well-being,
usage of SwissCovid App (FOPH 2020d), motivation to participate in study
X
BL baseline
Corona Immunitas: study protocol of a nationwide program
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and risk exposures as well as monthly follow-ups. Details
on the weekly and monthly follow-ups are found in
Table 3, and the questionnaires are in the supplementary
material. In some centers, groups of participants will fur-
ther be invited to participate in repeated in-person visits for
testing of their SARS-CoV-2 antibody levels.
Statistical analysis plan and sample size
calculation
There will be a centralized data management plan and a
centralized process for analyses done on pooled data from
all study sites. The primary endpoint for the overall study is
the seroprevalence of SARS-CoV-2 antibodies in the
general population at repeated time points during the
pandemic in Switzerland. From the data collected within
the seroprevalence studies of the randomly selected popu-
lation sample, we will determine the age-specific and time-
specific attack rate based on seroprevalence. We will also
calculate the age-specific and region-specific cumulative
incidence of seropositive individuals who have been
asymptomatic, age-specific distribution of disease severity
in seropositives who have been symptomatic, age-specific
and disease severity-specific geometric mean level of IgG/
IgA antibody titers, and lastly population groups most at
risk of being seropositive (e.g., age groups, sex, occupa-
tion). To estimate seroprevalence, we use a Bayesian
logistic regression model, accounting for the age and sex of
the general population, and weighted for the sampling
strategy (Stringhini et al. 2020). We integrate this regres-
sion model with a binomial model of the antibody test
sensitivity and specificity to adjust the estimates for test
performance while propagating uncertainty around test
performance into final seroprevalence estimates. Recent
observations suggest that antibodies could decrease if not
disappear with time (Ibarrondo et al. 2020; Long et al.
2020). If confirmed in larger and prospectively planned
studies (see Table 2), we will account for this trend by
modeling the impact on the estimated proportion of par-
ticipants having been infected.
The association of seroprevalence with participants’
characteristics, potential risk factors, and preventative
measures will be assessed by mixed multiple linear and
logistic regression analyses, with random effects for can-
tons, adjusted for potential confounders and will include
interaction terms if reasonable. Analyses will be conducted
in R (R Core Team 2020), with some sites conducting local
analyses using R or other software (e.g., STATA).
The sample size provides enough statistical power to
estimate the seroprevalence of SARS-CoV-2 antibodies
with reasonable accuracy in each Canton, for different age
groups, and at different points in time (sample sizes range
from n = 1200–8640 per Canton; Table 1). Estimates are
considered precise enough for informing policy-makers if
the entire 90% credible interval leads to the same inter-
pretation of seroprevalence and possible decisions. For
specific groups of interest (e.g., age group 65? or any
subpopulation), and considering a serological test with
98% sensitivity and 99% specificity, a minimum popula-
tion of 200 persons with an observed seroprevalence of 5%
will yield 90% credible intervals of ± 2.5% for a posterior
prevalence of 4.6%, of ± 3.5% for a posterior seropreva-
lence of 9.7% (observed prevalence 10%) and of ± 4.6%
for a posterior seroprevalence of 19.9% (observed preva-
lence 20%). We consider these precisions enough for
informing policy-makers. Site are free to have larger
samples per group of interest, and we will adapt the sample
size calculations once the seroprevalence is higher than
20%. For each age group, three sampling reserves (each
representing 25% of the needed sample size) will addi-
tionally be drawn by the FSO. The reserves will be used in
case of lower participation rate if the needed sample size is
not attained.
Results
The University of Geneva provided phase one estimates for
Geneva by enrolling 2766 participants from 1399 house-
holds with a demographic difference that mirrored the
Canton. When they began in April 2020, the seropreva-
lence was estimated at 4.8% (95% CI 2.4–8.0, n = 341)
(Stringhini et al. 2020). By the fifth week, the seropreva-
lence had risen to 10.8% (95% CI 8.2–13.9, n = 775). The
age group with highest risk of being seropositive was found
to be those aged 20–49 years.
The centers of Zurich, Lausanne, Basel City/Land,
Ticino, and Fribourg began recruitment for the second
phase of the study and have recruited 5973 participants. Of
those recruited, 1187, 1560, and 1677 participants have
completed the first, second, and third weeks of the digital
follow-up, respectively. A total of 900 participants have
completed the first monthly follow-up.
Given the results from phase one from Geneva and the
number of diagnosed cases of SARS-CoV-2 up to August
2020 across the Swiss Cantons, we expect declining sero-
prevalence rates from Southern to Northern and from
Western to Eastern Switzerland. Thus, for phase two we
may expect seroprevalences between 2 and 15% across
regions. For phases three (November 2020) and four
(March 2021), this may change considerably because the
pandemic now has substantially different numbers of new
cases within German- and French-speaking cantons.
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Discussion
Corona Immunitas is a research program coordinated by
SSPH?, conducting longitudinal, population-based sero-
prevalence studies covering a number of Swiss Cantons as
well as several seroepidemiological studies in specific
subpopulations. The population-based seroprevalence
studies are conducted on population samples that are rep-
resentative of the Cantonal populations, ensured by a ran-
dom selection of residents in the Cantonal population
registries. Studies on subpopulations cover various popu-
lations and are detailed in Table 2. Studies are mostly
cross-sectional and a number of them include nested lon-
gitudinal components to help capture much more than
serology estimates of the population.
Corona Immunitas addresses a number of limitations of
the current evidence in seroprevalence studies. One goal is
to conduct studies with low risk of bias and a sampling
strategy for both general and subpopulations that reflect the
target populations of interest as much as possible. We use
an accurate serology test and consistent questionnaires
across sites to give a clearer picture of the pandemic. The
longitudinal component of the program will provide guid-
ance as to the extent and duration of immunity, as well as
the long-term impact of the pandemic and lockdown
measures. Therefore, Corona Immunitas gives policy-
makers useful information for public health decisions.
Several investigators of Corona Immunitas are members of
the National COVID-19 Science Task Force of Switzerland
that directly advises the FOPH and Federal Council
(https://ncs-tf.ch/de/). Others are closely linked to cantonal
health authorities and stakeholders. On the cantonal level,
Corona Immunitas works with the respective health
authorities and aims to establish a science to policy col-
laboration with the federation of Cantonal health directors.
Finally, the program will provide information about the
impact of the pandemic and the effectiveness of protective
measures to decision makers for those persons with par-
ticularly exposed occupations and vulnerable persons.
Despite these efforts, there is potential for several lim-
itations. First, even though efforts were made to recruit
representative samples of the population by inviting ran-
domly selected residents from cantonal population reg-
istries, we expect a relatively low participation rate which
may introduce selection bias. Some reasons why individ-
uals might not participate include lack of time and moti-
vation, the fact that the assessment period of the second
phase coincided with the Swiss summer holiday, the fear of
being infected, and test fatigue (Bobrovitz et al. 2020).
Other risks of selection bias that could artificially increase
the estimated seroprevalence include stronger motivation
to participate if they are symptomatic, were in contact with
a person who tested positive for COVID-19, or travelled to
a severely affected area. Although the coordination is
strong on conceptual aspects of the study, practical aspects
differ between study sites. Study sites share a common
protocol, but some differences may still exist. To mitigate
the risk that these differences impact on the results, the
consortium will regularly compare SOPs and visit sites.
Finally, antibodies may not be detectable in those who had
a SARS-CoV-2 infection but with no or mild symptoms
(Long et al. 2020) and estimates may therefore underesti-
mate seroprevalence. However, the repeated serological
testing will provide important insights into the potential
disappearance of antibodies, factors associated with it and
allow for correcting estimates of the proportion of people
who had the infection.
One advantage of Corona Immunitas is to learn from
other existing seroprevalence studies worldwide and the
emergence of further evidence on the accuracy of sero-
logical tests as well as the nature of different tests. The use
of a combined data management plan and nationwide
serology test will guarantee interoperability and compara-
bility. Additionally, the common work allows the consor-
tium to cover different phases of the pandemic (https://
www.corona-immunitas.ch/program) and to study sub-
populations in a complementary way, which avoids
redundancies and increases exhaustiveness.
Another advantage of the Corona Immunitas program is
the combined use of serological testing and questionnaires.
Self-reported data on socioeconomic characteristics,
symptoms, and contact tracing will give rise to future
analyses, which will further the understanding of the pan-
demic in more depth than serological testing alone. It will
provide the possibility to assess severity of illness per
infection more accurately, as well as transmission
dynamics, and effect of socioeconomic characteristics.
Transmission parameters are important for assessing
transmission risks and shaping sanitary recommendations
tailored to workspaces, schools, or the private sphere, e.g.,
in households or for families, especially those with elderly
parents in nursing homes (McMichael et al. 2020).
Socioeconomic characteristics also need to be addressed,
especially social determinants of health (Khalatbari-Soltani
et al. 2020) and their relation with the disproportionate
impact of death and severe illness on social minorities
(Saini 2020). These populations can be disproportionately
affected by negative consequences of the pandemic from a
physical health, mental health and a socioeconomic per-
spective. Additionally, the subsequent digital follow-up
will provide data to help nourish a deeper understanding of
the pandemic and its related sanitary measures on mental
and physical health, and overall well-being of the popula-
tion and society.
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The Corona Immunitas program will inform on the
prevalence of the population infected by region and its
longitudinal components will inform on potential post-in-
fection acquired immunity and its duration. Corona
Immunitas is a unique nationwide research program that is
centrally coordinated, which maintains the independence of
all centers involved, ensuring both interoperability and
comparability, and the adaptation of study designs to local
needs. The Corona Immunitas consortium will generate
reliable, comparable and high-quality data with extensive
coverage of the Swiss geography and of several subpopu-
lations of interest, to inform governmental and sector-
specific decision making on the management of the SARS-
CoV-2 pandemic. It can serve as a template for other
regions and countries as it is important to have comparable
data to fight this pandemic most efficiently.
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E. A. West
123
Lausanne, Switzerland; vincent.faivre@unisante.ch), Jan Fehr, MD
(Epidemiology, Biostatistics and Prevention Institute, University of
Zurich, Zurich, Switzerland; jan.fehr@usz.ch), Andrea Felappi
(Center for Primary Care and Public Health (Unisanté), University of
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MAS, MD (Center for Primary Care and Public Health (Unisanté),
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